Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program

BACKGROUND: Belimumab is a recombinant, human, IgG1λ monoclonal antibody that targets B-lymphocyte stimulator. The intravenous formulation is indicated for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Belimumab has been formulated for subcutaneous (SC) administr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yapa, S Wickramaratne Senarath, Roth, D, Gordon, D, Struemper, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054300/
https://www.ncbi.nlm.nih.gov/pubmed/27072354
http://dx.doi.org/10.1177/0961203316642309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054300/
https://www.ncbi.nlm.nih.gov/pubmed/27072354
http://dx.doi.org/10.1177/0961203316642309

Ejemplares similares